Description
Medpace Holdings, Inc.: How Pre-Backlog Became Bigger Than Backlog—and Why That Changes the Pipeline Story!
Medpace Holdings Inc.’s third quarter 2025 earnings reflect a robust performance with record net bookings and a solid financial outlook. The company recorded revenue of $659.9 million, marking a 23.7% increase from the previous year, and net new business awards rose 47.9% year-over-year to $789.6 million, resulting in a book-to-bill ratio of 1.20. This growth can be attributed to strong initial award notifications and a 30% year-over-year increase in the total dollar value of awarded work not yet recognized in backlog. However, despite these positive trends, the company acknowledges a challenging customer funding environment, which remains a critical area of focus. The favorable performance was influenced by a productive therapeutic mix shift, particularly towards faster-burning metabolic studies with high reimbursable costs. This has increased the company’s pass-through costs, which represented approximately 42% of total revenue in the quarter, a level expected to remain similar in the near future.
